Trial Profile

Phase II Study of Pembrolizumab and Ipilimumab Following Initial Anti-PD1/L1 Antibody

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 08 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipilimumab (Primary) ; Pembrolizumab (Primary)
Indications Acral lentiginous melanoma; Malignant melanoma; Skin cancer
Focus Therapeutic Use

Most Recent Events

02 Mar 2023 Planned End Date changed from 1 Jun 2022 to 1 Jun 2026.
04 May 2021 Primary endpoint (Response rate per irRECIST) has been met, according to results published in the Journal of Clinical Oncology.
04 May 2021 Results assessing efficacy and safety of pembrolizumab plus low-dose ipilimumab after anti-PD-1/L1 immunotherapy failure in patients with advanced melanoma, published in the Journal of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com